VTE pre Flashcards
Unfractionated heparin (UFH)
-rapid, parenteral
-anticoagulant
-variable dose response
-weight-based dosing
Variable dose response of UFH
=need for aPTT monitoring
-aPPT = activated Partial Thromboplastic Time
-goal: 1.5-2.5 time control
Unfractionated heparin weight-based dosing
-initial: 80 units/kg IV bolus then 18 units/kg/hr infusion
-APTT < 35s (<1.2): 80/+4
–APTT 35-45s (1.2-1.4): 40/+2
-APTT 46-70s (1.5-2.5): no change
-APTT 71-90s (2.6-3): dec infusion rate by 2
Weight-based dosing of UFH monitoring
-aPTT at baseline
-6h after dose or with each dosage for first 24h
-check daily after first day
Heparin Associated Thrombocytopenia (HAT)
-HIT-type I
-non-immune mediated
-mild dec in platelets
-49-72 hours after admin of heparin
-transient
-do not need to d/c heparin
Heparin Induced Thrombocytopenia (HIT)
-immune mediated
-thrombotic complications
-7-14 days after taking heparin
-can occur up to 9 days after d/c
-platelets drop > 50% from baseline
HIT management
-stop all heparin
-give alt anticoagulant
-do not give platelet infusion
-do not give warfarin platelet count > 150k
-evaluate for thrombosis
Low molecular weight heparin
-better than UFH
-good availability
-predictable dose response
-no resistance
-fixed or weight-based dosing
-no need to monitor
-longer half-life qd or BID
-improved absorption bc smaller
-reduced risk of HIT and maybe bleeding
Low molecular weight heparin drugs
-enoxaparin
-dalteparin
Enoxaparin dosing prophylaxis
-30mg SQ q 12h (surgery)
-40mg SQ qd (medical
Enoxaparin dosing for treatment
-1mg/kg SQ q12
-1.5mg/kg SQ qd
Enoxaparin dosing for renal dysfunction
-30mg SQ qd
-1mg/kg SQ qd
Dalteparin dosing for prophylaxis
-2500-5000 units SQ qd
-200 units/kg SQ qd 30 days then 150 units SQ qd (cancer)
Monitoring parametersLMWH
-anti-Xa levels
-consider in kids, kidney failure, obesity, long course, pregnancy
Anti-Xa tx
-BID 0.6-1 units/ml 4h post dose
-dq: 0.1-0.3 units/mL obtained as trough
-can consider peak 1-2 units/mL obtained 4h post dose
Fondaparinux
-injectable Xa inhibitor (FXa)
-prophylaxis follwoing THA, TKA, hip replacement, ab surgery
-tx of DVT or PE
Fonaparinux dosing prophylaxis
-2.5mg SQ qd (hip, knee, ab surgery)
Fonaparinux dosing for DVT or PE tx
-<50kg: 5mg
-50-100: 7.5mg
->100: 10mg
-SQ qd
Fondaparinux considerations
-dont use in renal dysfunction (CrCl <30)
-do not use for prophylaxis w low body weight
-can use in HIT
-no monitoring
-pregnancy category B
IV direct thrombin inhibitors
-Lepirudin
-Bivalirudin
-Argatroban
Lepirudin
-IV direct thrombin inhibitor
-tx HIT
-0.15mg/kg/h +/1 0.4mg/kg bolus
-reduce dose if CrCl <60ml
Bivalirudin (angiomax)
-IV direct thrombin inhibitor
-0.7mg/kg then 1.75 mg/kg/h
-tx HIT, UFH alt during PCl
Argatroban
-2mcg/kg/min
-tx HIT
-elevates INR, overlap w warfarin unitl INR >4
-cautionhepatic dysfunctoin (0.5mcg)
Warfarin
-1-6mg
-2.5, 7.5, 10mg
-PO
-all tablets same color
Challenges of Warfarin
-narrow therapeutic window
-subject variability
-interactions
-labs hard to standardize
-good PK/PD understanding by bot patient/provider
Warfarin MOA
-inhibits enzymes that convert vit K
-inhibits Factors II, VII, IX, X
-inhibits protein C and S
-doesnt effect already formed thrombi
Warfarin PK
-effect within 24h
-peak 72-96h
-2-5 day duration
-CYp450 metabolism in liver
half/life of vit K factors
-prothrombin (II): 60-100h
-VII: 4-6h
-IX and X: 20-40
Warfarin genetic variances
-CYP2C9
-VKORC1